July 05, 2021

Phase 1 safety and tolerability study of IMB-1018972, a novel oral modulator of substrate utilization designed to improve cardiac metabolic efficiency and bioenergetics

June 22, 2021

Imbria Pharmaceuticals announces enrolment of the first 10 patients in IMPROVE-DiCE, an exploratory Phase 2 study investigating the impact of IMB-1018972 on cardiac energetics, metabolism and function in patients with type 2 diabetes

May 17, 2021

Imbria Pharmaceuticals Presents Phase 1 and Preclinical Data of IMB-1018972 (IMB-101), an Investigational Cardiac Mitotrope, at the American College of Cardiology 70th Annual Scientific Session & Expo